Skip Navigation

COVID-19 Update

Find a Doctor

Find a Researcher


Antonio Carlos Wolff, M.D.

Photo of Dr. Antonio Carlos Wolff, M.D.
  • Professor of Oncology

Languages: English, French, Portuguese, Spanish


Breast Cancer, Cancer Survivorship, Clinical Practice Guidelines, Medical Oncology, New Therapies in Breast Cancer, Quality Measures, Quality of Care, Risk Assessment and Early Detection more

Research Interests

Breast Cancer

Request an Appointment

Insurance Information



Outside of Maryland

Request Appointment

International Patients

Request Appointment


Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Appointment Phone: 410-955-8964
401 N. Broadway
Harry and Jeanette Weinberg Building
Baltimore, MD 21231 map
Phone: 410-614-4192

Johns Hopkins Medicine - Green Spring Station

Appointment Phone: 410-955-8964
10753 Falls Road
Johns Hopkins Kimmel Cancer Center, Pavilion II Suite 415
Lutherville, MD 21093 map
Phone: 410-583-2970


As a member of the Breast Cancer Program, the research efforts of Dr. Wolff have focused on improving the treatment options of patients with breast cancer, improving accrual to clinical trials, the implementation of research findings in clinical practice, and improving quality of care. He is also interested in the development of prognostic and predictive biomarkers (tissue, blood, and imaging), and collaborates with Johns Hopkins investigators in MRI Radiology in the development of new magnetic resonance imaging technologies as predictive tools for early response assessment in patients with operable breast cancer and with investigators in the Breast Cancer Program in the development of methylation marker tools for use in breast cancer. Dr. Wolff was a member of the Breast Cancer Guidelines Committee of the National Comprehensive Cancer Network (NCCN) between from 2000 to 2014.  In 2014 , Dr. Wolff became Co-Chair of the Breast Cancer Committee of the ECOG-ACRIN Cancer Research Group.

Dr. Wolff is past Chair (2006-7) of the Health Services Committee of the American Society of Clinical Oncology, which oversees ASCOs efforts in the development, dissemination, and implementation of practice guidelines, and he is a founding member of ASCOs Quality Care Committee. Dr. Wolff co-lead the international effort that led to the publications of the ASCO/College of American Pathologists Clinical Practice Guideline on HER2 Testing (2007) and Hormone Receptor Testing (2010) in Breast Cancer. In 2012, Dr. Wolff became an Associate Editor for the Journal of Clinical Oncology

Dr. Wolff is also interested in survivorship, needs assessments, and educational needs of breast cancer patients. He is also a member of ASCOs Pilot Testing of Treatment Summaries and Treatment Plans in clinical practice funded by Susan G. Komen for the Cure. At Johns Hopkins, he co-chairs the Cancer Outcomes & Health Services Research Interest Group that was formed to connect researchers across the Schools of Medicine, Nursing, and Public Health that are working in cancer outcomes and health services research. He is the 2011 chair of the Clinical Research Review Committee of the Johns Hopkins Kimmel Cancer Center, and a member of the School of Medicine CME Advisory Board.

Dr. Wolff has received peer-reviewed research funding from the National Cancer Institute, the Avon Foundation, the Breast Cancer Research Foundation, and The Susan G. Komen Breast Cancer Foundation (Maryland affiliate and national organization). He is also the Executive Officer of the Translational Breast Cancer Research Consortium (, a clinical research consortium that involves all breast cancer SPOREs and all major breast cancer programs. In 2009, Dr. Wolff received a National Cancer Institute Cancer Clinical Investigator Team Leadership Award. His clinical practice at Johns Hopkins is dedicated exclusively to the care of patients diagnosed with breast cancer.


Professor of Oncology
Member, Breast Cancer Program at The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Like many of his colleagues, Dr. Wolff dedicates his professional time both to caring for breast cancer patients and solving the mysteries that they present. “It is such a nice combination to be a doctor but also to be at the forefront of discussions with other researchers about what will influence care in the future, particularly in an environment like Hopkins, where we have such a strong multidisciplinary team,” Dr. Wolff says. 
During the fourteen-plus years that he has been a part of Hopkins’ medical team, the challenges Dr. Wolff’s patients face in the clinic have informed the questions he brings to the laboratory and to collaborators elsewhere working with him to improve the quality of breast cancer care. Some of those inquiries in which he has focused over the years include risk assessment, early detection, improved biomarkers as predictors of treatment benefit, and cancer survivorship. From micro-level investigations with fellow researchers at Hopkins to national initiatives in which he is either leading or participating, Dr. Wolff is making inroads in each of these areas of expertise. 
While so many areas of breast cancer research require urgent attention, Dr. Wolff currently is focusing much of his attention on improving the accuracy of routine tests that identify the specific subtype of breast cancer in newly diagnosed patients.
“That definition of the breast cancer subtype becomes the most critical determinant of decisions about what treatment patients should be offered in addition to surgery and possible radiation,” Dr. Wolff explains. And yet, in about 10 percent of all cases, the test results are wrong. Dr. Wolff has worked with leaders of the American Society of Clinical Oncologists and the College of American Pathologists to change that. “The efforts I have been a part of, at a national level, have impacted and improved the quality of biomarker testing in patients diagnosed with breast cancer,” Dr. Wolff says. 
Locally, Dr. Wolff is examining with Hopkins researchers Sara Sukumar and Ben Ho Park ways to develop improved biomarkers to measure, in blood, the presence or absence of specific gene mutations that indicate the presence and type of cancer. These biomarkers would be used in patients who had early stage breast cancer or whose cancer has spread to other sites (metastases). “It is critical for us to ensure that we give the right treatment to the right patient, minimizing the risk of unnecessary treatment and the development of side effects that could affect their quality of life,” Dr. Wolff says. 
Survivorship occupies a prominent place in Dr. Wolff’s breast cancer efforts. As research advances allow an increasing number of patients to live beyond breast cancer and focus on life after the disease, survivorship becomes a critical topic. That’s why Dr. Wolff helped to spearhead the Johns Hopkins Survivorship Program, which serves as a broad-based educational resource for survivors, their families, and non-cancer physicians. 
“There’s no question that breast cancer is scary, but in many cases it [the disease] is not what matters in the long run,” Dr. Wolff says. more


  • Professor of Oncology

Departments / Divisions

Centers & Institutes



  • MD, Faculdade de Medicina da Universidade Federal do Rio de Janeiro (1986)


  • MedStar Good Samaritan Hospital / Internal Medicine (1990)
  • The Mount Sinai Hospital / Internal Medicine (1991)


  • Washington University School of Medicine in St Louis / Hematology and Oncology (1992)
  • Johns Hopkins University School of Medicine / Medical Oncology (1995)

Board Certifications

  • American Board of Internal Medicine / Medical Oncology (1995)

Research & Publications

Clinical Trial Keywords

breast cancer, biomarkers, survivorship

Selected Publications

Carlson, R.W.; Brown, E.; Burstein, H.J.; Gradishar, W.J.; Hudis, C.A.; Loprinzi, C.; Mamounas, E.P.; Perez, E.A.; Pritchard, K.; Ravdin, P.; Recht, A.; Somlo, G.; Theriault, R.L.; Winer, E.P.; Wolff, A.C. NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw. 2006 Mar;4 Suppl 1:S1-26.

Carlson, R.W.; Moench, S.J.; Hammond, M.E.; Perez, E
.A.; Burstein, H.J.; Allred, D.C.; Vogel, C.L.; Goldstein, L.J.; Somlo, G.; Gradishar, W.J.; Hudis, C.A.; Jahanzeb, M.; Stark, A.; Wolff, A.C.; Press, M.F.; Winer, E.P.; Paik, S.; Ljung, B.M. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw. 2006 Jul;4 Suppl 3:S1-22; quiz S23-24.

Khatcheressian, J.L.; Wolff, A.C.; Smith, T.J.; Grunfeld, E.; Muss, H.B.; Vogel, V.G.; Halberg, F.; Somerfield, M.R.; Davidson, N.E. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol. 2006 Nov 1;24(31):5091-5097.

Wolff, A.C.; Davidson, N.E. Still waiting after 110 years: the optimal use of ovarian ablation as adjuvant therapy for breast cancer. J Clin Oncol. 2006 Nov 1;24(31):4949-4951.

Wolff, A.C.; Jones, R.J.; Davidson, N.E.; Jeter, S.C.; Stearns, V. Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support. J Clin Oncol. 2006 May 20;24(15):2392-2394; author reply 2394-2395.

Briest, S.; Wolff, A.C. Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer. Expert review of anticancer therapy. 2007 Sep;7(9):1243-1253.

Carlson, R.W.; Anderson, B.O.; Burstein, H.J.; Carter, W.B.; Edge, S.B.; Farrar, W.B.; Goldstein, L.J.; Gradishar, W.J.; Hayes, D.F.; Hudis, C.A.; Jahanzeb, M.; Ljung, B.M.; Kiel, K.; Marks, L.B.; McCormick, B.; Nabell, L.M.; Pierce, L.J.; Reed, E.C.; Silver, S.M.; Smith, M.L.; Somlo, G.; Theriault, R.L.; Ward, J.H.; Winer, E.P.; Wolff, A.C. Invasive breast cancer. J Natl Compr Canc Netw. 2007 Mar;5(3):246-312.

Cianfrocca, M.; Wolff, A.C. Optimizing endocrine therapy for premenopausal and postmenopausal women with breast cancer. Oncology (Williston Park). 2007 Jan;21(1):63-69; discussion 69, 72, 75 passim.

Messersmith, W.A.; Rudek, M.A.; Baker, S.D.; Zhao, M.; Collins, C.; Colevas, A.D.; Donehower, R.C.; Carducci, M.A.; Wolff, A.C. Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours. Eur J Cancer. 2007 Jan;43(1):78-86.

Moore, H.C.; Green, S.J.; Gralow, J.R.; Bearman, S.I.; Lew, D.; Barlow, W.E.; Hudis, C.; Wolff, A.C.; Ingle, J.N.; Chew, H.K.; Elias, A.D.; Livingston, R.B.; Martino, S. Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623. J Clin Oncol. 2007 May 1;25(13):1677-1682.

Ouwerkerk, R.; Jacobs, M.A.; Macura, K.J.; Wolff, A.C.; Stearns, V.; Mezban, S.D.; Khouri, N.F.; Bluemke, D.A.; Bottomley, P.A. Elevated tissue sodium concentration in malignant breast lesions detected with non-invasive 23Na MRI. Breast Cancer Res Treat. 2007 Dec;106(2):151-160.

Tan, S.H.; Wolff, A.C. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer. Clin Breast Cancer. 2007 Feb;7(6):455-464.

Wolff, A.C.; Hammond, M.E.; Schwartz, J.N.; Hagerty, K.L.; Allred, D.C.; Cote, R.J.; Dowsett, M.; Fitzgibbons, P.L.; Hanna, W.M.; Langer, A.; McShane, L.M.; Paik, S.; Pegram, M.D.; Perez, E.A.; Press, M.F.; Rhodes, A.; Sturgeon, C.; Taube, S.E.; Tubbs, R.; Vance, G.H.; van de Vijver, M.; Wheeler, T.M.; Hayes, D.F. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007 Jan 1;25(1):118-145.

Barone, B.B.; Yeh, H.C.; Snyder, C.F.; Peairs, K.S.; Stein, K.B.; Derr, R.L.; Wolff, A.C.; Brancati, F.L. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008 Dec 17;300(23):2754-2764.

Burstein, H.J.; Elias, A.D.; Rugo, H.S.; Cobleigh, M.A.; Wolff, A.C.; Eisenberg, P.D.; Lehman, M.; Adams, B.J.; Bello, C.L.; DePrimo, S.E.; Baum, C.M.; Miller, K.D. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008 Apr 10;26(11):1810-1816.
Higgins, M.J.; Wolff, A.C. Therapeutic options in the management of metastatic breast cancer. Oncology (Williston Park). 2008 May;22(6):614-623; discussion 623, 627-619.

Marchionni, L.; Wilson, R.F.; Wolff, A.C.; Marinopoulos, S.; Parmigiani, G.; Bass, E.B.; Goodman, S.N. Systematic review: gene expression profiling assays in early-stage breast cancer. Ann Intern Med. 2008 Mar 4;148(5):358-369.
Snyder, C.F.; Garrett-Mayer, E.; Brahmer, J.R.; Carducci, M.A.; Pili, R.; Stearns, V.; Wolff, A.C.; Dy, S.M.; Wu, A.W. Symptoms, supportive care needs, and function in cancer patients: how are they related? Qual Life Res. 2008 Jun;17(5):665-677.

Sparano, J.A.; Wang, M.; Martino, S.; Jones, V.; Perez, E.A.; Saphner, T.; Wolff, A.C.; Sledge, G.W., Jr.; Wood, W.C.; Davidson, N.E. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008 Apr 17;358(16):1663-1671.

Tan, S.H.; Wolff, A.C. The role of ovarian ablation in the adjuvant therapy of breast cancer. Curr Oncol Rep. 2008 Jan;10(1):27-37.

Wolff, A.C.; Berry, D.; Carey, L.A.; Colleoni, M.; Dowsett, M.; Ellis, M.; Garber, J.E.; Mankoff, D.; Paik, S.; Pusztai, L.; Smith, M.L.; Zujewski, J. Research issues affecting preoperative systemic therapy for operable breast cancer. J Clin Oncol. 2008 Feb 10;26(5):806-813.

Allred, D.C.; Carlson, R.W.; Berry, D.A.; Burstein, H.J.; Edge, S.B.; Goldstein, L.J.; Gown, A.; Hammond, M.E.; Iglehart, J.D.; Moench, S.; Pierce, L.J.; Ravdin, P.; Schnitt, S.J.; Wolff, A.C. NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. J Natl Compr Canc Netw. 2009 Sep;7 Suppl 6:S1-S21; quiz S22-23.

Baker, S.D.; Verweij, J.; Cusatis, G.A.; van Schaik, R.H.; Marsh, S.; Orwick, S.J.; Franke, R.M.; Hu, S.; Schuetz, E.G.; Lamba, V.; Messersmith, W.A.; Wolff, A.C.; Carducci, M.A.; Sparreboom, A. Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther. 2009 Feb;85(2):155-163.

Balmanoukian, A.; Zhang, Z.; Jeter, S.; Slater, S.; Armstrong, D.K.; Emens, L.A.; Fetting, J.H.; Wolff, A.C.; Davidson, N.E.; Jacobs, L.; Lange, J.; Tsangaris, T.N.; Zellars, R.; Gabrielson, E.; Stearns, V. African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women. J Clin Oncol. 2009 Aug 1;27(22):e35-37; author reply e38-39.

Carlson, R.W.; Allred, D.C.; Anderson, B.O.; Burstein, H.J.; Carter, W.B.; Edge, S.B.; Erban, J.K.; Farrar, W.B.; Goldstein, L.J.; Gradishar, W.J.; Hayes, D.F.; Hudis, C.A.; Jahanzeb, M.; Kiel, K.; Ljung, B.M.; Marcom, P.K.; Mayer, I.A.; McCormick, B.; Nabell, L.M.; Pierce, L.J.; Reed, E.C.; Smith, M.L.; Somlo, G.; Theriault, R.L.; Topham, N.S.; Ward, J.H.; Winer, E.P.; Wolff, A.C. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2009 Feb;7(2):122-192.

Connolly, R.; Wolff, A.C. Pregnancy and fertility with breast cancer: what are the options? Oncology (Williston Park). 2009 May;23(6):478, 481.

Emens, L.A.; Asquith, J.M.; Leatherman, J.M.; Kobrin, B.J.; Petrik, S.; Laiko, M.; Levi, J.; Daphtary, M.M.; Biedrzycki, B.; Wolff, A.C.; Stearns, V.; Disis, M.L.; Ye, X.; Piantadosi, S.; Fetting, J.H.; Davidson, N.E.; Jaffee, E.M. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol. 2009 Dec 10;27(35):5911-5918.

Kantsiper, M.; McDonald, E.L.; Geller, G.; Shockney, L.; Snyder, C.; Wolff, A.C. Transitioning to breast cancer survivorship: perspectives of patients, cancer specialists, and primary care providers. J Gen Intern Med. 2009 Nov;24 Suppl 2:S459-466.

Muss, H.B.; Berry, D.A.; Cirrincione, C.T.; Theodoulou, M.; Mauer, A.M.; Kornblith, A.B.; Partridge, A.H.; Dressler, L.G.; Cohen, H.J.; Becker, H.P.; Kartcheske, P.A.; Wheeler, J.D.; Perez, E.A.; Wolff, A.C.; Gralow, J.R.; Burstein, H.J.; Mahmood, A.A.; Magrinat, G.; Parker, B.A.; Hart, R.D.; Grenier, D.; Norton, L.; Hudis, C.A.; Winer, E.P. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009 May 14;360(20):2055-2065.

Partridge, A.H.; Wolff, A.C.; Marcom, P.K.; Kaufman, P.A.; Zhang, L.; Gelman, R.; Moore, C.; Lake, D.; Fleming, G.F.; Rugo, H.S.; Atkins, J.; Sampson, E.; Collyar, D.; Winer, E.P. The impact of sharing results of a randomized breast cancer clinical trial with study participants. Breast Cancer Res Treat. 2009 May;115(1):123-129.

Snyder, C.F.; Frick, K.D.; Kantsiper, M.E.; Peairs, K.S.; Herbert, R.J.; Blackford, A.L.; Wolff, A.C.; Earle, C.C. Prevention, screening, and surveillance care for breast cancer survivors compared with controls: changes from 1998 to 2002. J Clin Oncol. 2009 Mar 1;27(7):1054-1061.
Snyder, C.F.; Frick, K.D.; Peairs, K.S.; Kantsiper, M.E.; Herbert, R.J.; Blackford, A.L.; Wolff, A.C.; Earle, C.C. Comparing care for breast cancer survivors to non-cancer controls: a five-year longitudinal study. J Gen Intern Med. 2009 Apr;24(4):469-474.

Snyder, C.F.; Garrett-Mayer, E.; Blackford, A.L.; Brahmer, J.R.; Carducci, M.A.; Pili, R.; Stearns, V.; Wolff, A.C.; Dy, S.M.; Wu, A.W. Concordance of cancer patients'' function, symptoms, and supportive care needs. Qual Life Res. 2009 Oct;18(8):991-998.

Stein, K.B.; Snyder, C.F.; Barone, B.B.; Yeh, H.C.; Peairs, K.S.; Derr, R.L.; Wolff, A.C.; Brancati, F.L. Colorectal Cancer Outcomes, Recurrence, and Complications in Persons With and Without Diabetes Mellitus: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2009 Sep 3.
Zellars, R.C.; Stearns, V.; Frassica, D.; Asrari, F.; Tsangaris, T.; Myers, L.; DiPasquale, S.; Lange, J.R.; Jacobs, L.K.; Emens, L.A.; Armstrong, D.K.; Fetting, J.H.; Garrett-Mayer, E.; Davidson, N.E.; Wolff, A.C. Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer. J Clin Oncol. 2009 Jun 10;27(17):2816-2822.

Barone, B.B.; Yeh, H.C.; Snyder, C.F.; Peairs, K.S.; Stein, K.B.; Derr, R.L.; Wolff, A.C.; Brancati, F.L. Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis. Diabetes Care. 2010 Apr;33(4):931-939.

Chavez-Macgregor, M.; Litton, J.; Chen, H.; Giordano, S.H.; Hudis, C.A.; Wolff, A.C.; Valero, V.; Hortobagyi, G.N.; Bondy, M.L.; Gonzalez-Angulo, A.M. Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity. Cancer. 2010 Sep 1;116(17):4168-4177.

Chumsri, S.; Jeter, S.; Jacobs, L.K.; Nassar, H.; Armstrong, D.K.; Emens, L.A.; Fetting, J.H.; Lange, J.R.; Riley, C.; Tsangaris, T.N.; Wolff, A.C.; Zellars, R.; Zhang, Z.; Stearns, V. Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer. Clin Breast Cancer. 2010 Feb;10(1):40-45.

Hammond, M.E.; Hayes, D.F.; Dowsett, M.; Allred, D.C.; Hagerty, K.L.; Badve, S.; Fitzgibbons, P.L.; Francis, G.; Goldstein, N.S.; Hayes, M.; Hicks, D.G.; Lester, S.; Love, R.; Mangu, P.B.; McShane, L.; Miller, K.; Osborne, C.K.; Paik, S.; Perlmutter, J.; Rhodes, A.; Sasano, H.; Schwartz, J.N.; Sweep, F.C.; Taube, S.; Torlakovic, E.E.; Valenstein, P.; Viale, G.; Visscher, D.; Wheeler, T.; Williams, R.B.; Wittliff, J.L.; Wolff, A.C. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010 Jun 1;28(16):2784-2795.

Hammond, M.E.; Hayes, D.F.; Wolff, A.C.; Mangu, P.B.; Temin, S. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. J Oncol Pract. 2010 Jul;6(4):195-197.

Jacobs, M.A.; Stearns, V.; Wolff, A.C.; Macura, K.; Argani, P.; Khouri, N.; Tsangaris, T.; Barker, P.B.; Davidson, N.E.; Bhujwalla, Z.M.; Bluemke, D.A.; Ouwerkerk, R. Multiparametric magnetic resonance imaging, spectroscopy and multinuclear ((2)(3)Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer. Acad Radiol. 2010 Dec;17(12):1477-1485.

Partridge, A.H.; Archer, L.; Kornblith, A.B.; Gralow, J.; Grenier, D.; Perez, E.; Wolff, A.C.; Wang, X.; Kastrissios, H.; Berry, D.; Hudis, C.; Winer, E.; Muss, H. Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol. 2010 May 10;28(14):2418-2422.

Snyder, C.F.; Blackford, A.L.; Brahmer, J.R.; Carducci, M.A.; Pili, R.; Stearns, V.; Wolff, A.C.; Dy, S.M.; Wu, A.W. Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: an illustration with the Supportive Care Needs Survey and the QLQ-C30. Qual Life Res. 2010 Aug;19(6):837-845.

Snyder, C.F.; Stein, K.B.; Barone, B.B.; Peairs, K.S.; Yeh, H.C.; Derr, R.L.; Wolff, A.C.; Carducci, M.A.; Brancati, F.L. Does pre-existing diabetes affect prostate cancer prognosis? A systematic review. Prostate Cancer Prostatic Dis. 2010 Mar;13(1):58-64.

Stein, K.B.; Snyder, C.F.; Barone, B.B.; Yeh, H.C.; Peairs, K.S.; Derr, R.L.; Wolff, A.C.; Brancati, F.L. Colorectal cancer outcomes, recurrence, and complications in persons with and without diabetes mellitus: a systematic review and meta-analysis. Dig Dis Sci. 2010 Jul;55(7):1839-1851.

Peairs, K.S.; Barone, B.B.; Snyder, C.F.; Yeh, H.C.; Stein, K.B.; Derr, R.L.; Brancati, F.L.; Wolff, A.C. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol. 2011 Jan 1;29(1):40-46.

Activities & Honors


  • American Association of Cancer Research
  • American Society of Clinical Oncology
  • European Society of Medical Oncology

Professional Activities

  • Associate Editor for Breast Cancer, The Journal of Clinical Oncology, 2012
  • Vice-Chair, ECOG-ACRIN Breast Cancer Committee

Videos & Media

The Impact of Breast Cancer Treatment on Your Long-Term Health

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

  • ...Loading ratings...
  • ... 
  • ... 
  • ... 
  • ... 
  • ... 


Is this you? Edit Profile
back to top button